Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.
<h4>Objective</h4>To assess whether the incidence of systemic adverse events differs between those who used bevacizumab and those who used ranibizumab in the treatment of age-related macular degeneration (AMD).<h4>Methods</h4>A systematic literature search was conducted to id...
Guardado en:
Autores principales: | Wei Wang, Xiulan Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/18d4f918c97e45ed856a33bf575385c2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
por: Fischer N, et al.
Publicado: (2013) -
Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Dimitrios A Karagiannis, et al.
Publicado: (2009) -
Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication
por: Damasceno N, et al.
Publicado: (2012) -
Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan H, et al.
Publicado: (2014) -
Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration
por: Nishimura T, et al.
Publicado: (2012)